A Novel Gene-Silencing Protein Offers New Possibilities for Treatment of Cancer and Genetic Disorders
News Oct 26, 2009
A study published recently in the Proceedings of the National Academy of Science (PNAS) by a team of scientists headed by Professors Hélène Bierne and Pascale Cossart from the Pasteur Institute, in collaboration with colleagues form the CNRS and the French Agricultural Research Institute (INRA), identified a novel protein, BAHD1, which is responsible for changing DNA structure and silencing the expression of genes. Expression of pathological variants of genes may play a key role in causing various cancers and genetic disorders. The finding is part of the Spatelis research project, funded under the framework of ERA-NET PathoGenoMics, an initiative of the European Commission aimed at advancing transnational research in genome-based research programs on human-pathogenic microorganisms.
All the cells in any particular human body contain the same genetic information, and yet our body is made of very different cell types and tissues such as skin, brain or muscles. This is due to the fact that each cell type activates only a small subset of genes, rendering it unique and different from cell types. But how do cells "choose" what genes to turn on or off? They do so, among other means, by regulating the structure of chromatin, fibers made of DNA and proteins that constitutes our chromosomes. Chromatin may have tightly packed and condensed areas, where genes are silenced, or areas that are less densely packed and genes are activated. It is crucial to identify factors that regulate the chromatin structure since their alteration can lead to cancers, developmental abnormalities, and neurological disorders.
The protein identified by the French scientists, BAHD1, is such a factor, which behaves as a chromatin condensation machine at specific gene sites. In particular, BAHD1 silences IGF2, a gene mainly active during embryo development. This and other embryonic-development genes remain silent in healthy adults. However, in many human cancers these genes are inappropriately reactivated, causing the explosion of uncoordinated cell growth that is the hallmark of tumor formation.
"The discovery of the BAHD1 complex contributes to the understanding of how genes in cells of our body are regulated. Such knowledge could lead to new cancer therapies aimed at re-silencing inappropriately activated genes or to new prognosis markers," said Dr. Marion Karrasch-Bott, Coordinator of ERA-NET PathoGenoMics.
About ERA-NET PathoGenoMics
ERA-NET PathoGenoMics, a project funded by the European Commission, has been set up to establish sustained co-operation between national funding bodies and to co-ordinate their genome-based research programs on human-pathogenic microorganisms. The participating ERA-NET PathoGenoMics partner countries and funding institutions include: Austria, Federal Ministry for Science and Research (BMWF) and The Austrian Science Fund (FWF); Finland, Academy of Finland (AKA); France, Institut Pasteur (IP), Ministère de l'Enseignement supérieur et de la Recherche (MESR) and The National Agency for Research (ANR); Germany, Federal Ministry of Education and Resarch (BMBF) and Project Management Juelich (PTJ); Hungary, Hungarian Academy of Science (HAS) and Hungarian Scientific Research Fund (OTKA); Israel, The Chief Scientist Office, Israeli Ministry of Health (CSO-MOH); Latvia, Latvian Council of Science (LCS); Portugal, The Science and Technology Foundation (FCT); Slovenia, Ministry of Higher Education, Science and Technology (MHEST); Spain, Ministry of Science and Innovation. For further information, please visit www.pathogenomics-era.net
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.